BIT Capital’s Vaxcyte PCVX Stock Holding History

BIT Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,100	Closed	-$78.7K	–	163
2023 Q1	$78.7K	Sell	2,100 -5,578	-73%	-$237K	0.01%	128
2022 Q4	$368K	Buy	+7,678	New	+$301K	0.08%	95

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT Capital's PCVX Position: Q2 2023 in Review

BIT Capital sold out of Vaxcyte (PCVX) in Q2 2023, closing a stake of 2,100 shares — an estimated $78.7K sold.

BIT Capital first reported a position in PCVX in Q4 2022 and held it in 2 quarters. The position peaked at $368K in Q4 2022. 197 funds tracked by Wall St. Rank hold PCVX as of Q2 2023.

BIT Capital reported no remaining Vaxcyte position as of Q2 2023 after selling out during the quarter.
BIT Capital sold 2,100 Vaxcyte shares in Q2 2023, an estimated $78.7K.
BIT Capital first reported a position in Vaxcyte in Q4 2022 and held it in 2 quarters.
BIT Capital's Vaxcyte position peaked at $368K in Q4 2022.
197 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2023.

Based on BIT Capital's 13F filing for Q2 2023, filed 12 Feb 2025.